Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Single-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Effects and Immunogenicity of RN0361 in Adult Subjects With Elevated Triglycerides

Next Previous
Search
Trial Profile

A Phase 1, Randomized, Single-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Effects and Immunogenicity of RN0361 in Adult Subjects With Elevated Triglycerides

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RN-0361 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Adverse reactions; First in man
  • Sponsors Ikaria Bioscience

    • Most Recent Events

    • 17 Mar 2025 Results presented in a Rona Therapeutics media release
    • 17 Mar 2025 Status changed to recruiting, according to a Rona Therapeutics media release
    • 17 Mar 2025 According to Rona Therapeutics media release, The company plans to advance RN0361 development in HTG patients based on a favorable safety profile and sustained triglyceride (TG) reduction in a 6-month single dose phase 1 clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top